EMA Recommends New HCV, Cancer and MS Drugs for Approval

EMA Recommends New HCV, Cancer and MS Drugs for Approval

Submitted by admin on June 24, 2017 - 9:11am
Source: 
RAPS.org
News Tags: 
Europe
EMA
hepatitis C
multiple sclerosis
breast cancer
renal cell carcinoma
AbbVie
Maviret
Gilead Sciences
Vosevi
Biogen
Amgen
Samsung Bioepis
biosimilars
Humira
Novartis
Kisqali
EUSA
Fotivda
Headline: 
EMA Recommends New HCV, Cancer and MS Drugs for Approval

Do Not Allow Advertisers to Use My Personal information